Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127111591 | 12711159 | 1 | I | 20160726 | 0 | 20160902 | 20160902 | DIR | FDA-CTU | 82.00 | YR | M | N | 84.00000 | KG | 20160901 | N | PH | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127111591 | 12711159 | 1 | PS | ACYCLOVIR. | ACYCLOVIR | 1 | Oral | Y | D | 0 | 400 | MG | TID | ||||||
127111591 | 12711159 | 3 | C | APIXABAN | APIXABAN | 1 | 0 | ||||||||||||
127111591 | 12711159 | 5 | C | FINASTERIDE. | FINASTERIDE | 1 | 0 | ||||||||||||
127111591 | 12711159 | 7 | C | CREON | PANCRELIPASE AMYLASEPANCRELIPASE LIPASEPANCRELIPASE PROTEASE | 1 | 0 | ||||||||||||
127111591 | 12711159 | 9 | C | PROTONIX | PANTOPRAZOLE SODIUM | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127111591 | 12711159 | 1 | Ophthalmic herpes simplex |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127111591 | 12711159 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127111591 | 12711159 | Acute kidney injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
Event ID | CASEID | RPSR COD |
---|---|---|
127111591 | 12711159 | HP |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127111591 | 12711159 | 1 | 5 | DAY |